| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910877830003321 |
|
|
Autore |
Toth Peter P |
|
|
Titolo |
Practical lipid management : concepts and controversies / / Peter P. Toth, Kevin C. Maki |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Chichester, West Sussex, UK ; ; Hoboken, NJ, : Wiley-Blackwell, 2008 |
|
|
|
|
|
|
|
ISBN |
|
1-281-93939-0 |
9786611939397 |
0-470-69687-7 |
0-470-69688-5 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (264 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Hyperlipidemia - Treatment |
Coronary heart disease - Prevention |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Practical Lipid Management; Contents; Foreword; Preface; Acknowledgements; Chapter 1 Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview; 1.1 Early History of Cardiovascular Epidemiology; 1.2 Lipid Risk Factors are Central to Efforts at CHD Prevention; 1.3 LDL-C and CHD Risk; 1.4 LDL-C Lowering and CHD Risk Reduction; 1.5 Other Atherogenic Lipoproteins: Atherogenic Remnants; 1.6 HDL-C and CHD Risk; 1.7 Trends in Lipids and Lipid Management in the USA |
1.8 The National Cholesterol Education Program Evaluation Project Using Novel E-Technology (NEPTUNE) II SurveyControversy: Should a Measure of Atherogenic Lipoprotein Particle Number be used in Risk Assessment And/Or to Evaluate the Response to Lipid Therapy?; Chapter 2 Vascular Biology and Atherogenesis; 2.1 Introduction; 2.2 Arterial Structure; 2.3 Endothelial Cell Function and Dysfunction; 2.4 The Role of Monocytes and Lymphocytes; 2.5 Atheromatous Plaques; Chapter 3 Detection, Evaluation, and Treatment Goals for Lipid Disorders in Adults |
3.1 Matching Aggressiveness of Treatment to Absolute Risk3.2 Screening for Dyslipidemias; 3.3 Risk Stratification; 3.4 Steps in the |
|
|
|
|
|
|
|
|
|
|
|
Risk Stratification Process - Major Risk Categories; 3.5 Tips for Calculating the Framingham Risk Score; 3.6 Subcategories for Consideration of More Aggressive Optional Treatment Goals; 3.7 Very High Risk Patients, Optional LDL-C Goal <70 mg dl-1; 3.8 Moderately High Risk Patients, OPTIONAL LDL-C Goal <100 mg dl-1; 3.9 Treatment Goals for Patients with Elevated Triglycerides; 3.10 Triglycerides and HDL-C as Targets for Therapy |
Controversy: Should Treatment Guidelines Include Targets for the Total/HDL Cholesterol Ratio?Chapter 4 Therapeutic Lifestyle Changes in the Management of Lipid Disorders and the Metabolic Syndrome; 4.1 Nature and Nurture in the Development of CHD Risk Factors; 4.2 Lifestyle Factors as Determinants of CHD Risk in Populations; 4.3 Within Country Variations in Lifestyle and CHD Risk; 4.4 The Metabolic Syndrome; 4.5 Therapeutic Lifestyle Changes; 4.6 The TLC Diet; 4.7 Dietary Adjuncts: Viscous Fibers and Plant Sterol/Stanol Products; 4.8 Physical Activity and Weight Reduction |
4.9 Smoking Cessation4.10 Importance of Allied Health Professionals; Chapter 5 Management of Elevated Low-Density Lipoprotein Cholesterol; 5.1 Relationship between LDL-C and Risk for Cardiovascular Events; 5.2 Clinical Trial Support for Very Aggressive LDL-C Reduction for Those at Highest Risk; 5.3 Genetic Disorders Associated with Elevated LDL-C; 5.4 Atherogenic Impact of LDL-C; 5.5 Management of Elevated LDL-C; 5.6 Summary; Controversy: How Low Should We Go?; Controversy: Risks and Bene.ts of High-Dose Statin Therapy Versus Combination Lipid Drug Therapy |
Controversy: Do the Benefits of Low-Density Lipoprotein Cholesterol Reduction Depend Strictly on "How Low You Go" or also on "How You Get There"? |
|
|
|
|
|
|
Sommario/riassunto |
|
Lipid management is a key part of medical practice, affecting the prevention and treatment of several diseases, including diabetes, cardiovascular disease and stroke. A practical text on the clinical management of dyslipidemias, Practical Lipid Management balances conceptual development and pathophysiology with a straightforward approach to the identification and treatment of abnormalities in lipid metabolism. The book explores the role of novel risk markers in clinical practice, summarizes the current guidelines for lipid management, and offers a critical and systematic approach to i |
|
|
|
|
|
|
|
| |